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Abstract
SIDDHARTHA MANDAL: FUNCTIONAL DATA ANALYTIC
INFERENCE FOR SYSTEMS GOVERNED BY DIFFERENTIAL
EQUATIONS WITH APPLICATIONS
(Under the direction of Dr. Pranab K. Sen
and Dr. Shyamal D. Peddada)
The objective of this dissertation research is to develop formal statistical method-
ology for analyzing systems governed by ordinary differential equations (ODE). Ordi-
nary differential equations are commonly used to describe a wide variety of biological
and physiological phenomena. They arise in the description of gene regulatory net-
works, study of HIV dynamics and other infectious diseases and toxicology . This
work is motivated by physiologically based pharmacokinetic (PBPK) models in tox-
icology which are deterministic models used to describe chemical kinetics in human
or animal physiology. These models relate the concentration of chemicals in tissues
and blood to their rates of change and physiological parameters, such as tissue vol-
ume and blood flow, and metabolic parameters among others, through a system of
ODEs. Usual strategies of analyzing such models involve non-linear least squares
methodology which can potentially be computationally intensive. Often, some of the
existing procedures for modeling ODEs do not necessarily account for inter and intra-
individual variability that are common in multi-subject experiments. Using functional
data analytic methods, in this dissertation research, we provide a formal statistical
framework for drawing statistical inferences regarding subject specific and population
specific parameters in models governed by a system of ODE. One of the main features
of the proposed methodology is to cast the problem in a constrained inferential frame-
work and thus avoid solving the differential equations, which is often challenging and
iii
time consuming. Such a formulation allows for the possibility that all components
of the ODE may not adequately describe the underlying biological phenomena. The
proposed framework also allows the researcher to estimate both within and between
subject variability, while drawing statistical inferences at the individual as well as the
population level. We make as few assumptions as possible while taking into account
the underlying structure in the data. The proposed framework allows researchers to
compare parameters among several populations, such as different dose groups, while
adjusting covariates, whether discrete or continuous. Such inferences were not possi-
ble until now. We illustrate the proposed methodology using some simulated datasets
as well as a real dataset on benzene concentration in exhaled breath.
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Chapter 1
MOTIVATION
Many biological and chemical systems or processes can often be described using a
system of ordinary differential equations (ODE). Some common areas of application
include gene regulatory networks, viral dynamics, modeling of infectious diseases, im-
munology and toxicology. Researchers developing gene regulatory networks are often
interested in studying the changes in mRNA and protein concentrations over time
(Polynikis et al. (2009)). The rate of change in the concentration of mRNA of a
particular gene (and it’s related protein) depends on the instantaneous concentra-
tions, degradation and transcription rates, which can be mathematically expressed
through mass balance equations using ODE. The system of ODE involved in a net-
work provides a mathematical model for the gene regulatory network. In immunology,
a question of interest is to study the effect of viral infection on the human immune re-
sponse system. Viral infection induces a response in the system that converts normal
lymphocytes to antibody producing cells that resist and destroy viruses. The changes
in concentration of these cells over time, which can be modeled using ODE, provide
valuable information on immune response (Oprea et al. 2000). Similarly, in the case
of HIV infection, one may study the dynamics of viral infection by observing the pop-
ulation of naive cells, infected cells or viral load and their changes over time (Perelson
(2002)). Again ODE can be used to mathematically describe the phenomenon. There
are numerous such examples in biological and physical sciences where the underlying
processes are described using a system of ODE containing unknown model parameters
that are to be statistically estimated. In this dissertation we focus on applications
to toxicology where researchers model chemical kinetics, or the flow of chemicals in
human or animal body using a system of ODE. Although this work is motivated by
an application in toxicology, as described in this dissertation, the methodology devel-
oped here can be adapted to other contexts such as those described above.
Humans are exposed to a vast array of compounds, some of which are potentially
toxic and even carcinogenic while some are potentially beneficial to human health. In
classical toxicology researchers often investigate the toxicity of a chemical by deter-
mining the proportion of animals with adverse response (such as tumors or lesions)
at a given dose of the chemical. A pharmacologist may conduct similar studies but
is often interested in the opposite challenge, namely, to identify the efficacy of a
drug. Although such studies are important to determine whether a particular chemi-
cal is toxic or beneficial, they do not necessarily explain a chemical’s mode of action.
For example, when an animal is exposed to a chemical in the classical 2-year bioassay
conducted by the National Toxicology Program, a toxicologist can determine whether
the animal had a particular lesion or not. From the observed outcome, they cannot
determine how the body processed the chemical, although such determinations are
extremely important to understand the underlying mechanisms or mode of action of
the compound. As noted in Reddy et al. (2005), toxicologists and pharmacologists are
often interested in quantitatively investigating factors that determining the processes
of absorption, distribution, metabolism and excretion (ADME) in various parts of the
body such as, stomach, blood, liver, kidney etc. “Pharmacokinetics may be simply
defined as what the body does to the drug” (Benet (1984)).
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Suppose a person inhales a volatile chemical compound such as benzene. Then
the flow of the chemical through the person’s body can be described using the flow
diagram in Figure 1.1. The diagram is a schematic representation of human phys-
iology. Note that there exist variations to Figure 1.1 available in the literature to
describe kinetics of benzene and other volatile chemicals in general. A flow diagram
as shown in Figure 1.1 can be mathematically modeled using a system of ODE (as
described in Section 2.1).
Alveolar air
Lung Blood
Slowly perfused
tissue
Richly perfused
tissue
Fat
Bone Marrow
Liver
Exhaled airInhaled Air
Metabolites
Arterial BloodVenous Blood
Figure 1.1: A physiologically based pharmacokinetic model for volatile compounds
(Travis et al. (1990)).
Using such a model and the available data, a toxicologist is often interested in
understanding the chemical kinetics of benzene. Thus the typical problem of interest
is to estimate the unknown parameters of the model, along with their uncertainty
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estimates, that are specific to subject as well as population. Researchers are often
also interested in comparing the model parameters between two or more groups after
adjusting for covariates. The goal of this dissertation work is therefore to develop a
formal statistical framework and methodology for addressing these issues. Although
this dissertation work is motivated by data from toxicology, the methodology is fairly
general and can be applied to other contexts, such as those mentioned earlier.
4
Chapter 2
LITERATURE REVIEW
2.1 Physiologically Based Pharmacokinetic Modeling
Pharmacokinetics of a chemical can be modeled through systems of differential equa-
tions that represent mass balance equations for the flow of chemicals. Unlike in
usual statistical methodology, the model is specified to describe the derivatives of
the response variable and not the response itself. Due to the absence of closed form
solutions to the system of differential equations in most complex systems, we do not
have an explicit model describing the dependence of the response on the parameters
of interest from differential equation models. Hence the need for novel statistical
methods for analysis of the class of models governed by differential equations, not
necessarily restricted to pharmacokinetic modeling. For the current review, we shall
mainly focus on dynamic systems in toxicological and pharmacological areas.
The analysis of chemical kinetics can be compartmental or non compartmental.
Non-compartmental methods rely on estimating the total exposure to a chemical.
One such non-compartmental technique to estimate the total exposure is to study
the area under the curve (AUC) of a concentration-time graph (Denker et al. 2002).
For other metrics such as area under the moment curve (AUMC) or mean residence
time (MRT), one may refer to Dunne and King (1989). On the other hand compart-
mental models try to estimate the concentration-time graph using kinetic models.
The main idea behind compartmental pharmacokinetic models is that the animal or
human body can be thought of as a collection of interconnected compartments, usu-
ally the organs or tissues. Blood serves as the medium of transport for the chemical
between these compartments. The chemical flow typically is modeled through first
order kinetic mass balance equations that relate the rate of change of the concen-
tration of drug in each compartment to the present concentrations. Usually, these
equations are first order linear and/or non-linear differential equations with several
parameters. Pharmacokinetic modeling deals with understanding of chemical kinetics
through estimation and inference about these parameters. More specifically, popu-
lation pharmacokinetic modeling deals with studying the sources of variability that
affects the pharmacokinetics of a chemical for a group of individuals or a species. The
main objectives of population PK analysis is to identify and quantitatively estimate
variabilities affecting the pharmacokinetics for a population (Steimer et al. (1994),
Davidian and Giltinan (1995)).
In general pharmacokinetic modeling, volume of distribution and clearance are two
of the most important parameters that define the kinetics of a chemical while being of
biological use. For intravenous administration of a chemical, volume of distribution is
the volume in which a chemical is distributed immediately after administration in the
physiology. Clearance is the volume of blood/plasma that is cleared of the chemical
per unit time. There exist multi-compartment PK models involving multiple volumes
of distribution and clearances for each compartment. In spite of being useful to de-
scribe the pharmacokinetics of a population, the PK models and parameters are not
targeted to reflect the actual physiological and anatomical structures. This gave rise
to physiologically based pharmacokinetic (PBPK) modeling. These are models that
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incorporate physiological knowledge along with the processes of absorption, distri-
bution, metabolism and excretion (Reddy et al. (2005)). The differential equations
defining the model are characterized by parameters that reflect the physiology, for in-
stance tissue volumes or partition coefficients. This makes the model physiologically
more realistic or interpretable and eventually facilitates the applicability to varying
situations. In cases where the efficacy or toxicity of a chemical compound is highly
related to the concentration in the target tissue rather than the plasma concentration,
PBPK models are more useful than their PK counterparts (Yang et al. (2004)). Fur-
ther, one can infer about mechanistic behavior for the chemical of concern through
these models (Reddy et al. (2005)). An important use of PBPK models is extension
between different dose levels, routes of exposure and even between species (Gargas
et al. (2000)). Humans are commonly exposed to chemicals at low dose levels, for
instance through occupational exposure for a longer time. Simulating such an exper-
iment in laboratory settings would turn out to be infeasible. In such cases, PBPK
models can be used to extend the results from the animal studies using higher doses.
In some cases, a mere change in the value of the parameter would be enough while in
other cases the model structure might need to be changed (For instance, in case of a
pregnant woman, equations for the fetus need to be included).
PBPK models have been developed for several classes of chemical compounds,
such as halogenated alkanes, hydrocarbons, aromatic compounds, environmental pol-
lutants and metals to name a few. For example, O’Flaherty et al. (2001) described
a PBPK model for Chromium VI, Gentry et al. (2004) described it for arsenic and
Kawahara et al. (1999) for the drug digoxin. These models have different character-
istics due to the inherent chemical nature of the compounds and consequently the
organs involved in the ADME of the compound. The models also vary according to
the route of exposure or path of administering the dose (such as inhalation, dermal,
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gavage or intravenous). PBPK models are constantly subject to change in model
structure to incorporate possible metabolic pathways and metabolite formation to
obtain a better understanding of the underlying true phenomena.
The importance of PBPK modeling with respect to public health stems from a
number of facts. Chemicals such as lead or arsenic have adverse health effects in
humans (Porba et al. (2011)). Pollutants such as PERC or TCE have widespread
occupational uses while drugs contain several chemicals which may be beneficial or
harmful for the human physiology. PBPK models provide a framework to answer
questions about the mechanism of actions of such chemicals (Sweeney et al. (2009)).
These models also find use in risk assessment studies since behavior of the chemicals
change with dose levels, species or route of exposure (Haddad et al. (2001)). Valid
methods describing the chemical actions would be advantageous in categorizing risk
associated with these attributes. The widespread application of differential equa-
tion models as noted above makes it an important area for development of formal
statistical methodology for estimation and testing purposes.
2.1.1 General Model Structure
The examples stated earlier and their modeling approaches have a few things in
common. They are all defined by a set of differential equations governing the dynamic
processes. The general structure of a model defined through differential equations is
illustrated below.
Consider a model with p compartments. Let Z = (Z1, Z2, . . . , Zp)
′ denote the
vector of state variables in the p states. The system of differential equations that
describe the rate of change in Z at time t be given by:
Z˙ = F(Z, t,θ), (2.1)
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where Z˙ = d
dt
Z denotes the rate of change in Z at time t, F(.) is a p × 1 vector of
known functions, θ = (θ1, θ2, . . . , θm)
′ is a m× 1 vector of unknown parameters.
Here we provide the differential equations for the PBPK model of benzene that
we are trying to analyze using the data from the benzene inhalation experiment.
This would help illustrate the general model structure that we have presented. The
PBPK model for benzene inhalation is a five compartment model as shown in Figure
1.1. The inhaled benzene gets absorbed into the lung blood and is transported to
the various compartments through arterial blood. Benzene is transported back into
lungs through venous blood. There is no direct exchange of benzene between com-
partments. Metabolites form within the metabolizing compartments, bone marrow
and liver.
In the model equations, Aj denotes the amount of the chemical in the jth compart-
ment, CVj is the concentration of the chemical in the venous blood at the jth tissue
exit, Qj denotes blood flow rate, Vj is the volume and pj is the partition coefficient
for the jth compartment. Qt and Qalv are the total blood flow and the alveolar blood
flow respectively. Pb denotes the blood:air partition coefficient. Among the metabolic
parameters, Vmax denotes the maximum metabolism rate and km is the concentration
at which reaction rate is half of Vmax for metabolizing sites. Cart, Cven and Cexh
represent the concentration of benzene in arterial blood, venous blood and exhaled
breath respectively. The physiological parameters describing the PBPK model for
benzene as proposed by Travis et al. (1990) are listed in Table 2.1. Body weight is
denoted as bwt in the table.
For non-metabolizing sites, namely richly perfused tissues(rpt), slowly perfused
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Table 2.1: Values of physiological parameters for benzene PBPK model for human
subjects (Travis et al. (1990)).
Physiological parameter (Units) Symbol Value
Total cardiac output (l/min) Qt 6.2
Alveolar blood flow (l/min) Qalv 5
Tissue blood flow rates (l/min)
Richly perfused tissue Qrpt 0.44*Qt
Slowly perfused tissue Qspt 0.15*Qt
Fat Qfat 0.05*Qt
Bone marrow Qbm 0.05*Qt
Liver Qliv 0.25*Qt
Tissue volumes (kg)
Richly perfused tissue Vrpt 0.25*bwt
Slowly perfused tissue Vspt 0.58*bwt
Fat Vfat 0.19*bwt
Bone marrow Vbm 0.05*bwt
Liver Vliv 0.026*bwt
Blood:Tissue partition coefficients
(dimensionless)
Richly perfused tissue prpt 1.49
Slowly perfused tissue pspt 2.03
Fat pfat 1.49
Bone marrow pbm 16.22
Liver pliv 1.49
Blood:Air partition coefficient (di-
mensionless)
Pb 7.4
tissues(spt) and fat, the differential equations are
dAj
dt
= Qj(Cart − CVj), j ∈ {rpt, spt, fat}. (2.2)
(2.2) represents mass balance equations for the three classes of tissues using first order
kinetics. Here the rate of change in the amount of benzene in these tissues is directly
proportional to the instantaneous concentration in the tissue. Blood flow serves as
the rate constant since benzene is being delivered through blood.
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Bone marrow (bm) and liver (liv) are possible metabolizing sites for benzene.
Along with the usual first order kinetics, these compartments have an extra term that
shows non-linear Michaelis-Menten kinetics for the formation of metabolites such as
phenol. The equations for these sites and the metabolites (met) are as follows:
dAj
dt
= Qj(Cart − CVj)− Vmax(j)CVj
(km(j) + CVj)
, j ∈ {bm, liv}, (2.3)
dAmet
dt
=
Vmax(bm)CVbm
(km(bm) + CVbm)
+
Vmax(liv)CVliv
(km(liv) + CVliv)
. (2.4)
The concentrations in venous and arterial blood are expressed as
Cven =
∑
j∈{rpt,spt,fat,bm,liv}
QjCVj
Qt
, (2.5)
Cart =
QtCven +QalvCin
Qt +
Qalv
pb
, (2.6)
Cexh = Cart/Pb. (2.7)
Concentration in the venous blood at jth tissue exit is expressed as
CVj =
Aj
Vjpj
. (2.8)
(2.2)-(2.8) represent the PBPK model for benzene inhalation shown in Figure 1.1.
We relate this system of ODE with the notation of the general model structure. The
amount of benzene in the tissue compartments such as fat, liver etc. is considered as
Z. The functional dependence (linear and/or non-linear) of the rates of change on
the state variables, parameters as shown in (2.2)-(2.8) constitute F. In case of PBPK
models, the actual number of parameters are large, more than 30 in some cases.
Treating all parameters as unknown often renders the problem as inestimable due to
sparsity of data. To circumvent this problem, often in case of animal or human PBPK
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models, most of the physiological parameters are derived from toxicological literature
or previous studies. For example, the blood or tissue volume, blood flow through
tissues are similar for humans in general. Hence these physiological parameters are
derived from literature or previous studies and held constant while constructing and
analyzing the PBPK models. On the other hand some parameters like metabolic con-
stants or Michaelis-Menten constants are not experimentally determined and hence
serve as the parameters of interest. In order to analyze the PBPK model, we assume
that it is identifiable with respect to these unknown parameters. In the benzene
PBPK model, the metabolic parameters Vmax (in µg/min) and km (in µg/l) for liver
and bone marrow compartments comprise the unknown parameter θ.
We can similarly formulate the gene regulatory network problem in this frame-
work. Z would represent mRNA and protein concentrations of genes that are mea-
sured over time as well as the genes that are not measured but are known to be in
the gene regulatory network. The question of interest is to infer about the unknown
parameters (θ) which characterize the ODE describing the gene regulatory network.
Most often these parameters are rates of the processes of transcription, translation or
degradation of mRNA or proteins.
Several other applications such as viral dynamics, infectious disease modeling and
immunology use ODE systems to model biological phenomena. We summarize the
formulation of these applications in terms of state variables, functions and parameters
for a few such areas in Table 2.2.
2.1.2 Issues with Data and Design
Experimental design and data available are important facets of this research. Toxi-
cological studies usually record the incidence of adverse reactions (tumors or lesions)
12
Table 2.2: Some applications of the proposed methodology.
State variable Functions Parameters
Gene
regulatory
network
mRNA
concentrations or
gene expressions
Factors of
translation,
transcription,
degradation etc.
Rates of the
factors affecting
concentration or
expression
Viral
dynamics
Density of naive
cells, infected
cells, dead cells
Factors of
infection, death
etc.
Rates of viral
infection,
susceptibility etc.
Infectious
diseases
Number of
susceptible,
infectious and
cured people
Factors
influencing birth,
death, infection
Rates of contact,
transition
Immunology Proportion of
centroblasts,
centrocytes
Factors of
mutation,
selection,
proliferation
Rates of
mutation,
selection etc.
Toxicology Amounts or
concentration of
chemicals
Factors of
chemical
processes, eg:
absorption,
metabolism
Metabolic
parameters,
Rates of reaction
in exposed subjects, after exposure to a dose of a chemical. On the other hand, stud-
ies recording chemical concentrations in the body measure the concentration of the
chemical over time in fluids such as blood or urine. Tissue samples are usually not
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available, since getting repeated samples from liver, kidney or muscles from human or
animal subjects is not feasible. However in certain animal studies, where the animals
are sacrificed at the end of the study, tissue samples may be available. Hence in
analysis of PBPK models, data are available for at most two or three compartments.
Measurement times are another important aspect of design and data. Chemical
concentrations are measured at specified time points after exposure to dose. Com-
partments that are measured may not have same measurement times. For example,
it is easy to get urine measurements more frequently, however getting blood measure-
ments too frequently may be difficult in case of rats and mice. For the same reason,
subjects may be measured at only a subset of the measurement times. The frequency
of dosing is also important since some studies are single dosage while others are mul-
tiple dosage studies. All these factors must be taken into account while planning the
analysis of differential equation models.
2.2 Non-linear Least Squares and Bayesian Approaches
In this section we describe some existing methods to analyze PBPK models. One
of the most widely used method is the non-linear least squares method as used in
Parham et al. (2002). The overall idea of this approach is to minimize the distance
between the data and the solution of the system of differential equations. Since the
differential equations do not have an explicit solution, the method involves the numer-
ical optimization of the differential equations using algorithms such as Nelder-Mead
algorithm or the Runge-Kutta method and obtaining the residual sum of squares be-
tween the data and predicted values of the observed compartments. Mathematically,
θˆ = arg minθ ‖ Z − Z(θ) ‖2, where Z(θ) is the numerical solution of the system
given by (2.1) for a particular θ. It is a non-linear optimization problem and there
are several computational and statistical challenges associated with this approach.
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Notable computational difficulties include lack of convergence or convergence to local
solution, computation time, convergence to local solutions due to irregular surface of
the residual sum of squares, especially for stiff differential equation systems (Ramsay
et al. (2007)). Due to these issues, it is difficult to obtain valid estimates of vari-
ability, drawing statistical inferences and testing hypotheses about the parameters of
interest.
In the last two decades, significant research has been conducted in the field of
non-linear regression in repeated measurements (Davidian and Giltinan 1995). This
methodology has been applied to models defined by differential equations (Tornøe
et al. 2004). As in the non-linear least squares methodology, these methods also rely
on solving the system of differential equations and often using their first order Taylor
series expansion as the regression function in a non-linear regression setup. In a mixed
effects scenario, a hierarchical model is developed with the data centered around the
numerical solution of the differential equations system and information is pooled over
all individuals to obtain parameter estimates in a likelihood framework. This method
still requires the solution of the differential equations and also is computationally
intensive due to the integration over the random effects for each individual.
An alternative to the above approaches is the Bayesian methodology (Bois 2000).
Hierarchical models are used to obtain the posterior distributions of the model pa-
rameters. There are three levels of modeling in this approach, namely individual
model, parameter model and error model. Individual model specifies the distribution
of the response variables, usually taken to be normal or lognormal. The solution
of the system of differential equations is taken as the location of these distributions
while the error model specifies the variability in the individual model. The prior
distribution of parameters and the individual model provide the joint distribution of
the data and the parameters, which is used to obtain the posterior distributions of
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the model parameters. It is clear in this approach that it relies on the accuracy of the
system of differential equations to model the phenomenon in the individuals and the
population as a whole. Also diagnostics for these models have not been developed
yet.
Recently in 2006 the US Environmental Protection Agency (EPA) conducted an
international workshop entitled, “The International Workshop on Uncertainty and
Variability in PBPK Models” to evaluate the available statistical methodology for
analyzing PBPK models. In a publication resulting from the workshop, Barton et al.
(2007) concluded that there is a need for a formal statistical methodology for ana-
lyzing PBPK models and to derive uncertainty estimates associated with parameter
estimates.
2.3 Functional Data Analytic Approaches
Ramsay (1996) introduced a functional data analytic (FDA) method to solve the
problem of parameter estimation in differential equation models known as Principal
Differential Analysis (PDA). The methodology consists of approximating the state
variables in the differential equations through some basis functions. These are linear
combinations of some functions of time, such as polynomials or cubic splines. These
approximations are made such that they also satisfy some regularization conditions.
Usually the approximations are penalized by placing some constraints on the second
or higher order derivatives of the approximations. The model parameters are esti-
mated by minimizing the residuals using the data and the approximated values of the
response variables. These methods have been mainly used in engineering dynamics
problems, such as the constantly stirred tank reactor problems.
On similar lines, a smoothing approach for parameter estimation in differential
equation models was proposed by Ramsay et al. (2007). In this paper, the authors
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used a basis expansion using B-splines to approximate the state variables like previous
instances. However, here the differential equations are treated as a regularization cri-
terion, accompanied by a regularization parameter. So one could decide on how much
confidence could be placed on the model itself. This comprised the inner optimization
of the method. The outer optimization comprised of minimizing the predicted resid-
uals. Approximate sampling variances of the parameter estimates were provided and
behavior of the parameter estimates were studied when the value of the regularization
parameter was large.
Poyton et al. (2006), Varziri et al. (2008b) carried forward the work on Principal
Differential Analysis by introducing an iterated version. They carried out a simultane-
ous optimization procedure on the basis parameters as well as the model parameters.
To arrive at the properties of the estimates, they used a maximum likelihood approach
and denoted the estimator by Approximate Maximum Likelihood Estimator(AMLE).
Varziri et al. (2008a) used AMLE in presence of unmeasured states and stationary and
non-stationary model disturbances. These methods were shown to work on several
engineering problems. However these were primarily for population estimation only.
Individual inferences and estimation of variance components were not addressed in
these works.
Liang and Wu (2008) approached a similar problem in a slightly different man-
ner. A two stage smoothing approach was employed. They used local polynomial
smoothing to approximate the response variables. But there was no regularization of
the basis parameters based on the differential equations. Instead, for estimating the
model parameters, the estimated values of the response variables and their deriva-
tives were plugged into the differential equation system and the residual error in the
differential equation system was minimized. No data points are involved in this stage
of the methodology and hence it was named Pseudo Least Squares estimator. So it
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was a method which was not exactly the same but close to the measurement error
approach. Consistency and asymptotic normality were proved for the estimator un-
der certain regularity conditions. The method was applied to simulated examples
and also real data on HIV CD4 cell counts. This methodology requires all the state
variables in the system of differential equations to be observable, which is rarely the
case in toxicological modeling situations. Also the population estimation methodol-
ogy was not discussed in this paper. In Table 2.3 we summarize the main features of
the above discussed papers and our contribution.
Table 2.3: Main features of some recent papers based on Ramsay et al. (2007) com-
pared to the proposed methodology.
Feature
Varziri et al. Liang and Wu Proposed
(2008b) (2008) Methodology
1. Allows for unobservable compo-
nents.
Yes No Yes
2. Basis approximation uses the data
and the differential equations.
Yes No Yes
3. Subject specific inference. No Yes Yes
4. Population based inference. Yes No Yes
5. Separate estimation of variance
components.
No No Yes
In this paper we extend Ramsay (1996) and Ramsay et al. (2007) methodology
to conduct formal statistical inferences by taking into account potential correlations
between and within compartments in a subject as well as between and within subject
variability. Although the focus of this paper is on analyzing PBPK models, the
methodology is sufficiently general and can be applied to other contexts according to
the formulations described in Table 2.2.
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2.4 Summary
Statistical treatment of differential equation models is a relatively newer area of re-
search with respect to theory and methodology while boasting of a wide range of
applications in public health and other fields. Traditional methods of analysis are
ridden with problems of several kinds and hence newer methodology based on func-
tional data analysis is an important alternative. Addressing issues such as parameter
identifiability and design of experiments are important foundations while developing
statistical methodology for these models and accounting for variability and uncer-
tainty provides a complete statistical framework on these basic foundations.
In Chapter 3, the proposed estimation methodology based on functional data anal-
ysis is provided with the necessary details and justification for its use. Asymptotic
properties are also shown in the same chapter. Chapter 4 describes the statistical
methodology to incorporate covariate effects in models defined through systems of
differential equations. In Chapter 5, all the proposed methodologies are illustrated
using simulated data examples and a real life study based on the same Benzene PBPK
model. Chapter 6 describes some of the future research problems that follows from
the current work.
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Chapter 3
ESTIMATION METHODOLOGY
IN DIFFERENTIAL EQUATION
MODELS
Modeling of systems of differential equations is different from usual statistical mod-
eling in the sense that the model in consideration does not describe the response
variable directly. The mathematical model describes the rate of change in response
variables and often the dependence of the response on the parameters are not known
explicitly. Some variants may also include algebraic equations that relate the response
variables themselves, along with the differential equations. This unique situation de-
mands a novel approach that combines the traditional statistical methods with newer
methods of functional data analysis. Motivated by the assessment in Barton et al.
(2007), this chapter intends to provide a statistically rigorous framework for analyzing
PBPK models. We cast the statistical problem in a general framework by exploiting
the functional data analytic methods available in the literature. In this chapter, we
present the proposed methodology for estimation of the individual and population
parameters and variability in the estimates along with confidence intervals.
3.1 Description
As described earlier, the state variables are related to each other through differential
equations. Due to unavailability of explicit solutions, the functional data analytic
approach provides an alternative way to solve this problem. The state variables,
whether observed or unobserved are approximated using basis functions, which are
functions of time. This provides a familiar platform based on regression which is
used to estimate the model parameters, first on an individual basis and finally for
population parameters. The proposed methodology thus tries to strike a balance
between the data available and the system of differential equations that we consider.
Table 3.1 defines the common notations that will be used in this thesis henceforth.
Other notations will be defined as they are used.
Table 3.1: Notations used in this work.
Symbol Meaning
Z State variables
Zo Observable state variables
Zu Unobservable state variables
Y Data on observable state variables
θ Model parameter
α Basis parameter
φ(Φ) Basis function(s)
λ Regularization parameter
i Index for individuals
j Index for states
k Index for time points
3.2 Methodology
We describe the methodology as two components, individual and population estima-
tion of model parameters.
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3.2.1 Individual Parameter Estimation
Let p denote the total number of states (or compartments) in a PBPK model. As
often is the case, suppose only d out of p compartments are measurable for the ith sub-
ject, i = 1, 2, .., n. Suppose Zi(t) = (Zi1(t), Zi2(t), . . . , Zid(t), Zi(d+1)(t), . . . , Zip(t))
′ =
(Zoi (t),Z
u
i (t))
′ denotes the vector of state variables in the p states at time t, where
Zo denotes the observable and Zu denotes the unobservable part. Let the system of
differential equations that describe the rate of change in Zi be given by:
Z˙i = F(Zi, t,θi), (3.1)
where Z˙i =
d
dt
Zi denotes the rate of change in Zi at time t, F(.) is a p × 1 vector of
known functions, θi = (θi1, θi2, . . . , θim)
′ is the vector of unknown parameters.
Let the observed value of the true state variable Zoi be denoted by Yi. Thus we
have
Yi = Z
o
i + ei, (3.2)
where ei is the component that captures the intra-individual variation in the data.
In some experimental settings where none of the compartments are observed directly,
the observed variable may be a function of the state variables in the model. For
instance, if concentration in exhaled breath is the the only observed variable, it can
be expressed as a weighted average of the concentrations in the other compartments,
which are not observed. Such a case would imply Yi = g(Z
u
i ) + ei, where g(.) is a
known function from the specified model.
One may assume that eij are independently distributed for all i with mean 0 and
aj × aj covariance matrix Σij(t). It is reasonable to assume that the intra-individual
correlation between measurements would decrease with amount of separation in time.
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Hence as commonly used in time-series models for a parsimonious description of
dependence in data (for example, Box, 2008), we let
Corr(eij(t1), eij′(t2)) =
 ρ
|t1−t2|
i(j) j = j
′;
ρ
|t1−t2|
i(j,j′) j 6= j′.
Lastly we model inter-individual variability by imposing a hierarchical structure on
θi. We shall assume that θi are identically and independently distributed with mean
θ and covariance matrix Ψ, which estimates the inter-individual variability.
We begin by estimating parameters for each individual subject. For notational
simplicity, we drop the indices for individuals. The functional basis approach (Ramsay
et al. 2007) is used to approximate the state variables Z in (3.1). This amounts to
selecting a class of basis functions, such as spline or polynomials, to approximate Zi.
In this article we use B-splines as the basis functions. Let Z˜ij(t), j = 1, . . . , p be the
approximate value of compartment j at time t, described through Lj basis functions.
Then
Z˜ij(t) = (Z˜
o
ij(t), Z˜
u
ij(t))
′ =
Lj∑
l=1
φijl(t)αijl = φij
′(t)αij ,
where φij(t) is a vector of basis functions and αij is a vector of unknown basis pa-
rameters.
Let αi = (αi1, . . . ,αip)
′ and Φ = diag(φi1
′(t), . . . ,φip
′(t)). Hence the approxi-
mated state variable for the ith individual is
Z˜i(t) = (Z˜i1(t), . . . , Z˜ip(t))
′ = Φiαi. (3.3)
The basis parameter vector αi are determined such that Z˜
o
i closely mimics the data
and the state variables Z˜i satisfies the system of differential equations. Hence both
Z˜i and Z˜
o
i are functions of the nuisance parameters αi.
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The objective is to estimate the unknown parameter θi for each individual, how-
ever, αi and ρi are unknown nuisance parameters that need to be estimated. We
begin by estimating αi, ρi and λi such that the “distance” between the observed Yi
and the approximated value Z˜oi is minimized subject to Z˜i satisfying the underlying
differential equations, in similar lines as a ridge regression problem. We can formulate
the problem of obtaining the approximation as follows:
minαi,ρi‖Σ(ρi)−1/2(Yi − Z˜oi (αi))‖22 subject to {αi : Φ˙iαi = F(Φiαi, t,θi)}
Thus, for a given θi, we minimize H(αi, ρi, λi) with respect to αi, ρi and λi:
H(αi, ρi, λi) =(Yi − Z˜oi (αi))′Σ(ρi)−1(Yi − Z˜oi (αi)) (3.4)
+ λi
∫
(Φ˙iαi − F(Φiαi, t,θi))′(Φ˙iαi − F(Φiαi, t,θi))dt.
In the above expression, λi is a regularization parameter which is estimated in the
above objective function. The estimators αˆi, ρˆi and λˆi obtained by minimizing (3.4)
are implicit functions of θi. Hence the estimated state variables
̂˜
Zi and therefore
̂˜
Zoi
are implicit functions of θi. For notational simplicity, we denote the predicted value of
the observable state variable by
̂˜
Zoi (θi). Using the estimators derived by minimizing
(3.4), we minimize the following quadratic form to estimate the model parameter θi:
S(θi) = (Yi − ̂˜Zoi (θi))′Σ(ρˆi(θi))−1(Yi − ̂˜Zoi (θi)). (3.5)
Expressions (3.4) and (3.5) are iteratively optimized until convergence. Using Taylor
series expansion of θˆi,we obtain an approximate covariance matrix of θˆi|θi given by(
dθˆi
dZoi
)
Σi(ρˆ)
(
dθˆi
dZoi
)′
, henceforth denoted by Γ(θi) in this paper.
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3.2.2 Population Parameter Estimation
Using the estimators obtained for each individual subject, we now describe the method
to estimate the population parameters. Towards this, as commonly done in non-linear
mixed effects models, we assume the following hierarchical model structure for θˆi and
θi.
Assumptions A:
(A.1) θˆi|θi are independently distributed with mean θi and covariance Γ(θi).
(A.2) θi|θ are i.i.d with mean θ and covariance Ψ.
Consider the marginal distribution of θˆi. Moments of the marginal distribution are
E(θˆi) = Eθ(E(θˆi|θi)) = θ.
Cov(θˆi) = Ψ +
∫
Γi(θi)p(θi|θ)dθi
= Vθ.
Thus our population level model is,
θˆi = θ + δi, Cov(δi) = Vθ. (3.6)
This is a Type III nonlinear marginal model described in Demidenko (2004). Our
objective is to estimate the population parameter θ and the covariance matrix of
the estimator of θ. Since Vθ is a function of θ, the classical iterated weighted least
squares type methodology is not applicable here. Demidenko (2004) suggests a Total
Generalized Estimating equation approach for such a formulation.
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Note that the score equation ∂l
∂θ
= 0 reduces to
n∑
i=1
[
V−1θ (θˆi − θ) +
1
2
G′[(V−1θ (θˆi − θ)⊗V−1θ (θˆi − θ))− vec(V−1θ )]
]
= 0, (3.7)
where G = ∂vec(Vθ)
∂θ
. The Fisher information matrix is given by Iθ = V−1θ + 12G′(V−1θ ⊗
V−1θ )G.
However TGEE is difficult to implement in the present problem, since the explicit
form of Vθ is unknown and a likelihood framework may not be appropriate in this
case. Hence we resort to the an empirical Bayes based technique and MINQUE
methodology (Rao, 1972) to solve the problem.There exists a well developed literature
on MINQUE and has been used in a wide range of contexts. In Zhang et al. (2000)
MINQUE based methodology was developed for estimating variance components in
non-linear mixed effects models, under heteroscedastic as well as homoscedastic errors.
We exploit their methodology for deriving the starting values for θ and Ψ for solving
(3.7) iteratively. Note that MINQUE of Zhang et al. (2000) is itself is an iterative
procedure involving iteration between two equations.
Ψˆ =
1
n
n∑
i=1
(θˆi − θˆ)(θˆi − θˆ)′ and
θˆ =
( n∑
i=1
(Ψˆ + Γˆi)
−1
)−1 n∑
i=1
(Ψˆ + Γˆi)
−1θˆi. (3.8)
Equivalently it can be implemented as noted below. We start with initial estimates
of θ and Ψ, obtained from
θˆ(0) =
1
n
n∑
i=1
θˆi and Ψˆ(0) =
1
n
n∑
i=1
(θˆi − θˆ(0))(θˆi − θˆ(0))′.
We iterate between the two following steps:
Step 1 : Update estimate of θi as
θˆi,(c+1) = (Γˆ
−1
i + Ψˆ
−1
(c))
−1(Γˆ−1i θˆi + Ψˆ
−1
(c) θˆ(c)),
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where Ψˆ(c) and θ(c) are the estimates from the cth iterate.
Step 2: Update the population parameter estimates as
θˆ(c+1) =
1
n
n∑
i=1
θˆi,(c+1) and Ψˆ(c+1) =
1
n
n∑
i=1
(θˆi − θˆ(c+1))(θˆi − θˆ(c+1))′.
Let Ψˆ and θˆ denote the estimates upon convergence. Let V̂θ = Ψˆ +
1
n
n∑
i=1
Γ(θˆi).
3.3 Asymptotic Properties of the Proposed Estimators
To explore the properties of the proposed estimators we need certain regularity as-
sumptions as mentioned in Nagaraj and Fuller (1991).
Assumptions B:
(B.1) The components of the model function F(.) are continuous and twi-
ce differentiable for θ0 ∈ B, a closed ball, where θ0 is the true par-
ameter vector.
(B.2) The matrix of partial derivatives D(θ) =
dF
dθ
is of full rank with p-
robability 1 in a neighborhood of θ0.
(B.3) The matrix Bt = H
−1/2
t Λ(t)
′Λ(t)H−1/2t and B
−1
t converges to posi-
tive definite matrices for large t, where Ht = diag(hiit) is a sequen-
ce of diagonal matrices such that hiit →∞ as t→∞.
The iterative individual parameter estimation problem can be viewed as a con-
strained linear regression problem subject to non-linear constraints dictated by the
system of differential equations. Since the observed data is a perturbation of the
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approximated observable state variables, we have
Yi = Z˜
o
i (αi) + i, subject to f(αi,θi) = 0. (3.9)
Owing to the fact that Zi = Φiαi, (3.9) can be formulated as
Yi = Λiθ
∗
i + i, subject to f(θ
∗
i ) = 0. (3.10)
Then the unconstrained least square estimate θˆ
∗
i = θ
∗
i + [Λ
′
iΛi]
−1Λ′ii.
Lemma 3.1 (Nagaraja and Fuller, 1991): Under Assumptions B, H
1/2
t (θˆi − θi) =
Op(1), where θi is the true parameter value for the ith individual.
Hence as the number of time points increase, the individual parameter estimates θˆi
is consistent for the true individual parameter value θi.
The individual parameter estimates obtained are θˆi, i = 1, . . . , n. Using delta
method, we obtain an approximate covariance matrix of the estimator as Γ(θi). Cor-
responding estimator of the covariance is Γ(θˆi). Since θˆi is consistent, by delta
method, Γ(θˆi) is consistent for Γ(θi), since Γ(.) is a continuous function. This can be
easily shown since f(.) is continuous and θˆi is a continuous function of Yi.
We make certain model assumptions for the population parameter estimation in
Assumption A in Section 3.2.2. Therefore the marginal covariance of θˆi is
E[θˆi − θ][θˆi − θ]′ = E[θˆi − θi + θi − θ][θˆi − θi + θi − θ]′
= E[θˆi − θi][θˆi − θi]′ + E[θi − θ][θi − θ]′
= E[Γ(θi)] + Ψ. (3.11)
From convolution of density functions and Assumption (A.2), E[Γ(θi)] is a function
of θ only. Hence θˆi are independent and identically distributed random variables.
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The iterative population parameter estimation involves calculating θˆ and Ψˆ. Let
Wi =
( n∑
i=1
(Ψ + Γi)
−1
)−1
(Ψ+Γi)
−1 and Wˆi =
( n∑
i=1
(Ψˆ + Γˆi)
−1
)−1
(Ψˆ+Γˆi)
−1. Then
θˆ =
n∑
i=1
Wˆiθˆi and θ˜ =
n∑
i=1
Wiθˆi. To prove the consistency of θˆ, we first prove the
consistency of θ˜ and then appeal to Slutsky’s theorem.
From the Noether’s condition for weighted least square estimators, if
(i) max1≤j≤n[w′nj(W
′
nWn)
−1wnj]→ 0 as n→∞ and
(ii) lim
n→∞
n−1(W′nWn) = V
∗, finite and positive definite,
then θ˜ is consistent for θ for large n.
The weights Wi need to be estimated in our case. Hence we study the behavior
of the variance components that serve as weights.
Theorem 3.1 Under Assumptions A and B,
(a) Ψˆ
pr−→ Ψ as t, n→∞
(b) 1
n
n∑
i=1
Γ(θˆi)
pr−→ E[Γ(θi)] as t,n →∞
Proof : (a) Ψˆ is the sum of square of residuals in the marginal individual parameter
estimates.
Ψˆ =
1
n
n∑
i=1
(θˆi − θˆ)(θˆi − θˆ)′
=
1
n
n∑
i=1
(θˆi − θ + θ − θˆ)(θˆi − θ + θ − θˆ)′
=
1
n
n∑
i=1
{(θˆi − θ)(θˆi − θ)′ + (θ − θˆ)(θ − θˆ)′
+ (θˆi − θ)(θ − θˆ)′ + (θ − θˆ)(θˆi − θ)′}. (3.12)
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Consider the first term in (3.12).
1
n
n∑
i=1
(θˆi − θ)(θˆi − θ)′
=
1
n
n∑
i=1
(θˆi − θi + θi − θ)(θˆi − θi + θi − θ)′
=
1
n
n∑
i=1
(θˆi − θi)(θˆi − θi)′ + 1
n
n∑
i=1
(θi − θ)(θi − θ)′ + 1
n
cross products. (3.13)
The second term in (3.13) converges to Ψ due to Assumption (A.2) as n → ∞.
The rest of the terms converge to 0 as t → ∞ due to the individual level parameter
consistency and as n→∞. Hence Ψˆ pr−→ Ψ as n, t→∞.
(b) To prove (b) it is enough to show that for any two m × 1 vector a1 and a2,∣∣∣a′1[ 1n n∑
i=1
Γ(θˆi)− E[Γ(θi)]
]
a2
∣∣∣ pr−→ 0 as t, n→∞.
∣∣∣a′1[ 1n
n∑
i=1
Γ(θˆi)− E[Γ(θi)]
]
a2
∣∣∣ (3.14)
=
∣∣∣a′1[ 1n
n∑
i=1
Γ(θˆi)− 1
n
n∑
i=1
Γ(θi)
]
a2 + a
′
1
[ 1
n
n∑
i=1
Γ(θi)− E[Γ(θi)]
]
a2
∣∣∣
= |Z1 + Z2|
≤ |Z1|+ |Z2|.
Consider Z1 = a
′
1
[
1
n
n∑
i=1
{Γ(θˆi) − Γ(θi)}
]
a2. Recall for each i, Γ(θˆi) − Γ(θi) are
marginally independent and identically distributed random variables and Γ(θˆi) −
Γ(θi) = op(1) for large t. Consider a random variable
Ui =
 a
′
1{Γ(θˆi)− Γ(θi)}a2 if |a′1{Γ(θˆi)− Γ(θi)}a2| < 
0 otherwise
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Note that
n∑
i=1
P (Ui 6= a′1{Γ(θˆi)−Γ(θi)}a2) <∞. By Khintchine equivalence lemma,
Strong Law of Large Numbers(SLLN) holds for both sequences of random variables
or none. For large values of t, E(Ui) = 0. Hence we can apply Khintchine Strong
Law of Large Numbers on Ui for large n. Since SLLN holds for Ui, i = 1, . . . , n, it
holds for a′1{Γ(θˆi)− Γ(θi)}a2. Hence |Z1| pr−→ 0.
From Assumption (A.2), θi are i.i.d random variables. By Strong Law of Large
numbers 1
n
n∑
i=1
Γ(θi)
pr−→ E[Γ(θi)], which implies |Z2| pr−→ 0. Hence (3.14) converges
in probability to 0 as n, t→∞.
Hence using Slutsky’s theorem and Theorem A.1, the proposed population variance
estimate V̂θ = Ψˆ +
1
n
n∑
i=1
Γ(θˆi) is consistent for Vθ as t, n→∞.
3.4 Variations in Design of Experiments
Toxicological studies often differ with respect to design of the study. Such varying
situations need to be accounted for in the proposed methodology for the differen-
tial equation models fitted to the data. Consider an experiment where the response
variable for each individual is measured at different times. This is a common occur-
rence in both animal and human studies. For instance, blood measurements from
mice may be drawn at different time points for groups of mice. Consequently, for
the ith individual in the study, the measurement time points are {t1, . . . , tni}. The
individual parameter estimation procedure would thus be based on the individual
measurement sets only. The intra-individual correlation structures (Σi) would be ap-
propriately modified to retain the same structure only with different orders (ni×ni).
Hierarchical model assumptions about θˆi and θi remain unchanged. The proposed
methodology would apply in the same way for this situation due to the formulation
of the problem based only on the model parameters.
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A different (but not exclusive) situation that might arise in such studies is the
measurement of multiple compartments with different observation times for each
compartment. For example, a study might be observing chemical concentrations
in both exhaled breath and blood. Exhaled breath measurements are usually more
easily available than blood observations. These situations can be readily incorpo-
rated in the provided formulation. In this case the data for an individual would be
(Yblood,Yexh)
′, where Yblood represents the concentrations in blood and Yexh are the
concentrations in exhaled breath at respective measurement times. Further, this sit-
uation may warrant the choice of different basis functions for the two compartments.
Hence we can visualize and tackle different design situations arising in toxicological
studies in context of differential equation models with the proposed methodology.
3.5 Discussion
Modeling systems of differential equation plays an important role especially in con-
text of pharmacokinetic and toxicokinetic modeling. Although such models are widely
used in a variety of contexts, as noted in the recent EPA workshop and the result-
ing publication (Barton et al. 2007) there does not exist a well developed statistical
methodology for drawing inference on the model parameters. This research, which
exploits the functional data analytic approach of Ramsay et al. (2007), takes the first
step towards a formal statistical theory and methodology. Specifically, an impor-
tant contribution of the proposed methodology is that it accounts for; (i) inter and
intra-individual variability, (ii) the dependence within subjects and between com-
partments/states. Secondly, our methodology overcomes the computational burden
of usual strategies by avoiding the problem of numerically solving a system of differen-
tial equations. This in turn also alleviates situations where the differential equations
explain the behavior of the chemical better in some compartments than others. In
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Chapter 5, the proposed methodology has been illustrated using simulated data ex-
amples and real data example based on a benzene inhalation experiment.
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Chapter 4
ACCOMMODATING
COVARIATES IN
DIFFERENTIAL EQUATION
MODELS
Most toxicological studies investigating the response to chemicals in human or ani-
mals also record covariate information on the individuals in the study. These may
include variables such as age, dose or weight. A question of interest to researchers
would be whether and how these variables affect the chemical phenomena. Often
chemical kinetics differ with changes in dosage or age of the subject. Some chemical
processes might be expressed more when the dose is low than higher doses. In this
chapter we try to provide approaches for covariate inclusion and testing in context to
the differential equation models described in the earlier chapters.
4.1 Existing Literature
Models governed by systems of differential equations can be visualized as a form of
non-linear regression problem with an unknown functional form of the regression at
the response. Hence we first explore the literature for methods of covariate inclusion
and testing in the non-linear regression problem and then focus on the methods for
the same in differential equation modeling.
4.1.1 Non-linear Regression Problem
In usual strategies for estimation in differential equation models, the problem of in-
terest is treated as a non-linear parameter estimation problem, where the dependence
of response on the parameters is the solution to the system of differential equations.
Consider a non-linear regression problem,
Y = f(U,θ) + , (4.1)
where f represents the non-linear regression function. Here U represents the covari-
ates. Usually in such a problem, the functional form f is known. The estimation
procedures involve minimizing the residual sum of squares,
SS = (Y − f(U,θ))′(Y − f(U,θ)), (4.2)
with respect to θ. The estimate of θ thus depends on the covariates U. However the
dependence is an implicit one and thus testing for the covariate effects is difficult.
One has to compare models by inclusion and exclusion of covariates, using likelihood
ratio statistics. Note that the usual model selection criterion like AIC would not work
in such situations due to the absence of a nested model structure.
A more recent methodology, namely varying coefficient models, developed for
incorporation of covariate effects was proposed by Hastie and Tibshirani (1993) and
later used by Sentu¨rk and Mu¨ller (2006). They developed this methodology in the
context of linear regression models. More recently, Cui et al. (2009) developed the
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varying coefficient model methodology to solve the problem of covariate adjusted non-
linear regression.
Originally, Hastie and Tibshirani (1993) proposed the varying coefficient model
to incorporate effects of latent covariates in the parameters of the linear regression
problem. The framework suggested that the coefficients in a linear regression model
be allowed to vary as smooth functions of some covariates. So the modified linear
regression model in a simple Gaussian univariate case can be represented as
Y = X1β1(R1) + . . .+Xpβp(Rp) + , (4.3)
where X and R are two kinds of covariates in the model, explicit and implicit. The
response is modeled as a linear function of the explicit covariates but the coefficients
are functions of the implicit ones. So the parameters (β(.)) represent an interaction
between these two classes of covariates. The estimation procedure in this case used a
penalized spline approach to estimate the unknown functions (β(.)) which served as
estimates for effects of the explicit covariates (X) adjusted for the implicit covariates
(R). The paper also highlighted some general models that can be described through
the same formulation.
Sentu¨rk and Mu¨ller (2006) and Cui et al. (2009) approached the problem from
the response modification angle. According to them, the response variable and the
predictors are modified by the latent covariates through multiplicative factors. Math-
ematically, the general non-linear model in this varying coefficient framework can be
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expressed as
Y = f(X, β) + , (4.4)
Y˜ = ψ(R)Y,
X˜r = φr(R)Xr, r = 1, . . . , q,
where Y is an unobservable response, X = (X1, . . . , Xq)
′ is an unobservable predictor,
β is the unknown model parameter, f is a known continuous function and Y˜ and X˜r
are the actual observable response and covariates. Further, ψ(.) and φr(.) are the
unknown distorting functions of the observed variable R. The methodology involves
estimation of the distorting function non-parametrically by regressing the predictors
and response on the distorting covariate, under some restricting conditions on the
expected values of ψ(R) and φr(R). The predicted response (
ˆ˜Y ) and predictors ( ˆ˜Xr)
are subsequently used in a non-linear parameter estimation framework to minimize a
L2 norm under (4.4).
All these state of the art methodologies in the area of covariate adjustment model
the response in terms of covariates. Also in case of the non-linear problem men-
tioned in Cui et al. (2009), the functional form of the regression function is given.
Further, the distorting functions are multiplicative in nature which might not be a
right choice in all situations. More importantly in all the cases, the dependence of
the response on the covariates is explicitly known. Also the model parameters here
directly measure the effect of the covariates on the response. Although these meth-
ods are effective ways to deal with covariate effects in non-linear regression models,
alternative methods must be explored to study covariate effects in models defined by
system of differential equations due to the peculiarities in the model structure and
formulation that distinguishes them from the usual non-linear regression model.
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4.1.2 Covariate Effects in PBPK Modeling
The focal point of a physiologically based pharmacokinetic model is a system of dif-
ferential equations that define the kinetics of a chemical in the physiology over time.
Covariates affecting the kinetics often take a secondary position in the analysis. In
a non-linear mixed effects framework or Bayesian approach to estimate parameters
in a system of differential equations, the key element is the numerical solution to the
ODE system. To include covariates in the analysis, the dependence of the system on
covariates must be explicitly known. This is often not the case in PBPK models.
Models defined by differential equations and in the special case of PBPK mod-
els, knowledge about the parameters determines the system completely. However,
in the analysis of covariate effects in PBPK models, the effect of covariates on the
parameters of interest are not often analyzed, even though this seems to be the more
intuitive way of differentiating between PBPK models for different groups based on
their covariate value. Most methods investigate the effect of covariates on the re-
sponse variable through a mixed effects or Bayesian framework. We look at a few
references to illustrate the state of the art in incorporation of covariate effects in
PBPK models, using both the non-linear least squares and the Bayesian approaches.
Joerger (2012) in a recent paper on pharmacokinetic modeling reviews the latest
approach to include covariates in a PBPK model for analysis using non-linear mixed
effects modeling techniques. The paper centers around the pharmacokinetic modeling
of anti-cancer drugs. Covariates are extremely important in cancer studies to provide
a more accurate modeling while taking into account the variability induced by the
variation in the covariate values. Some major covariates in pharmacokinetic studies
for anti-cancer drugs include weight, gender, glomerular filtration rate and body sur-
face area. The paper lists explicitly the relationships between the pharmacokinetic
parameters and some of the covariates (both categorical and continuous) of interest
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for specific anti-cancer drugs. For example, in the pharmacokinetics of busulfan in
children, the clearance parameter (CL) is related to weight (WT) in the following
way :
CL = 4.04L/h/20kg · (WT/20)0.74.
In case of a drug pemetrexed, the clearance parameter (CL) is mathematically related
to the glomerular filtration rate (GFR) according to the following :
CL = 43 + 47.2 · (GFR/92.6).
These structural dependencies of the parameters on the covariate are fed into the
non-linear mixed effects framework through the solution of the system of the dif-
ferential equations. As is evident from the above examples, specific covariates are
explicitly included in the PBPK model itself. Thus solving the system numerically
would provide an implicit functional dependence on the covariates. This approach to
covariate modeling is feasible only if the mathematical relationships are well known
from literature. For a more general covariate analysis of any system of differential
equations, this approach would not be applicable due to lack of knowledge about the
dependencies.
The Bayesian methodology for analyzing PBPK models also take covariates into
account in a similar way. In a recent publication, Mo¨rk et al. (2009) describe a
Bayesian analysis of a washin-washout PBPK model for acetone. The authors use
a Bayesian hierarchical model to study the chemical kinetics for acetone in human
physiology. The PBPK model for acetone used in this paper describes the kinetics
of acetone through multiple tissue compartments and observes the concentration of
acetone in arterial blood and exhaled breath. Some of the covariates considered were
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body weight, height and endogenous acetone levels. These covariates featured explic-
itly in the system of differential equations describing the PBPK model. The Bayesian
model assumptions used the solution of the differential equations as the location for
the distribution of the data points. Hence as in the non-linear mixed effects approach,
the covariate effects are only present if one knows the actual mathematical formula-
tion of the covariates in the PBPK model. Problems would arise if the covariates are
not present in the original system of differential equations.
In both the approaches described above, testing for particular covariate effects is
impossible due to the peculiarities in the formulation of the problem. In contrast to
a regression problem (Y = Xβ + ), there are no parameters that describe the effect
of a covariate in a differential equation model. This makes it difficult to test whether
the covariates have an effect on the response. Further, if one is interested in testing
the effects of covariates on the parameters of interest in the PBPK model, these ap-
proaches are not appropriate. Hence tests of hypothesis on the effects of covariates
have not been formulated in case of models defined by system of differential equations
and is a relevant research problem.
To summarize, testing of covariate effects in non-linear models has been an es-
pecially challenging problem often due to lack of explicit structural form of depen-
dence. This deficiency is more stark in the case of models dictated by differential
equations. Especially in case of physiologically based pharmacokinetic models where
the unknown parameters are usually metabolic parameters or rate constants, the de-
pendence on covariates of interest are more difficult to infer. This calls for a more
structured methodology to test for covariate effects in PBPK models, and models
governed by differential equations in general. In this chapter, we propose a method
for covariate inclusion, estimation of the model parameters while accounting for the
covariates and testing of hypothesis about covariate effects in differential equation
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models, in light of the functional data analytic approach used in Chapter 3. The
methodology has been illustrated using simulated data examples and a real dataset
from a benzene inhalation study.
4.2 Problem Description
Models governed by differential equations are inherently different from usual statis-
tical models such as regression models in terms of covariate inclusion. Consider a
simple linear regression model given by
Y =Xβ + . (4.5)
Here covariates X are included explicitly in the model and the effect of the covariates
are expressed through the parameters β. This model thus makes it convenient to test
effects of the covariates on the response Y. However in case of the models we have
been considering, neither the parameters nor the covariates are as in (4.5). Consider
the model
Z˙ = F(Z, t,θ). (4.6)
The model parameter θ in (4.6) are physiological or metabolic parameters and not
indicative of the covariate effects. Another important aspect to be noted here is that
there are no explicit covariates in the differential equation model (4.6). These are the
two main questions that motivate the work done in this chapter.
The main objectives of this section is to explore methodology to incorporate co-
variates in differential equation models, specifically physiologically based pharmacoki-
netic (PBPK) models and develop methodology to investigate effect of covariates on
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the parameters and/or response variables, based on the functional data analytic esti-
mation methodology proposed in Chapter 3. This would facilitate the formulation for
measuring the effects of covariates in a sound statistical framework without having
to solve or simulate the system of differential equations.
4.2.1 Incorporation of Covariates
The primary question is the formulation of the problem as to how the covariates
feature in the model. The covariates may affect the parameters and/or response. In
this chapter, we develop a methodology where the model parameters are dependent
on the covariates. This would implicitly mean that the response or state variables
are dependent on the covariates only through the model parameters. Suppose there
are q covariates to be considered. Suppose θi = (θi1, . . . , θim)
′ denote the m × 1
model parameter, ηi be a vector of order m(q + 1) × 1 and Ui be the (q + 1) × 1
covariate vector for the ith individual, taking into account the intercept term also.
Let {g : Rm(q+1) → Rm} be a one-one link function between θi and ηi. The proposed
formulation implies
θi = g(Ui,ηi). (4.7)
Hence the entire problem setup now focuses on ηi. The simplest model that we
can adopt is when g(.) is linear, that is θi = diag(Ui, . . . , Ui)ηi = Uiηi. Often in
PBPK models, the parameters of interest are metabolic parameters or rate constants
which are always strictly positive. Hence the dependence of model parameters on the
covariates need to be modeled differently. One such formulation can be log(θik) =
Uiηik, where θik and ηik are the kth component of θi and ηi respectively. This
approach to the problem provides a simple yet intuitive approach to address questions
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regarding the effect of covariates on model parameters.
The model in (4.6) is now expressed as
Z˙i = F(Zi, t, g(Ui,ηi)). (4.8)
The complete state variable Z is comprised of observable (Zo) and unobservable state
variables (Zu). Data on the observable state variables for the ith individual are
denoted by Yi. Hence, for each individual Yi = Z
o
i + i, where i denotes the intra-
individual error for the ith individual with mean 0 and covariance matrix Σ(ρi). As
in the previous chapter we impose a structure on Σ(ρi) to obtain a parsimonious
representation of intra-individual variability.
Using basis function expansion for the state variables Zi, we obtain a similar
individual parameter estimation procedure as described in Section 3.2.1. Let the
basis functional expansion of Zi be denoted by Z˜i = Φiαi, where Φi is a function of
time. Hence both Z˜oi and Z˜
u
i re functions of αi. We have to minimize the distance
between the data and the approximation while ensuring that the approximations
minimize the error in the differential equations. Therefore, the objective functions
for estimation of the transformed parameters are
S1(αi, ρi, λi) =(Yi − Z˜oi (αi))′Σ(ρi)−1(Yi − Z˜oi (αi)) (4.9)
+ λi
∫
(Φ˙iαi − F(Φiαi, t, g(Ui,ηi)))′(Φ˙iαi − F(Φiαi, t, g(Ui,ηi)))dt
and
S2(ηi) = (Yi − ̂˜Zoi (ηi))′Σ(ρˆi(ηi))−1(Yi − ̂˜Zoi (ηi)). (4.10)
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In the individual estimation procedure, the intermediate parameter estimates, αˆi, ρˆi
and λˆi are all functions of ηi and Ui. Hence the predicted value of Z˜
o
i is a function
of ηi. We minimize Equations (4.10) to obtain the estimated parameters, denoted as
ηˆi, which are functions of the individual data Yi and the individual covariates Ui.
Hence using delta method, we have
ηˆi(Yi, Ui) ' ηˆi(Zoi , Ui) + (Yi − Zoi )
dηˆi(Yi, Ui)
dYi
∣∣∣
Yi=Zoi
.
Cov(ηˆi(Yi, Ui)) '
[dηˆi(Yi, Ui)
dYi
∣∣∣
Yi=Zoi
]
Cov(Yi)
[dηˆi(Yi, Ui)
dYi
∣∣∣
Yi=Zoi
]′
.
Corresponding estimate of the actual model parameters is θˆi = g(Ui, ηˆi) and by
delta method, it’s asymptotic covariance is given by [g′(Ui, ηˆi)]Cov(ηˆi,Ui)[g
′(Ui, ηˆi)]
′,
where g′(.) is the derivative of g(.) with respect to ηi.
We assume that the conditional distribution of ηˆi|ηi have mean ηi and covariance( dηˆi
dZoi
)
Σˆi
( dηˆi
dZoi
)′
(denoted by Γ(ηi, Ui)), which depends on the covariate Ui for the ith
individual and the true individual parameter ηi. Also to indicate that the individuals
are sampled from a common population, we assume that the true individual parame-
ter ηi has a distribution with mean η and covariance matrix W. Hence the marginal
distribution of ηˆi is centered at η and has a covariance matrix W + Eη[Γ(ηi, Ui)],
which is a function of the population level parameter η and the individual covariate
value Ui. Hence marginally the estimated individual parameter values are indepen-
dent but not identically distributed. As for the actual model parameters θi, they are
not identically distributed as in the previous chapter.
We shall use the proposed methodology to perform population estimation on the
modified parameters ηi. Consider the following model for ηˆi.
ηˆi = η + ζi, (4.11)
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where ζi are independent with mean 0 and covariance W + Eη[Γ(ηi, Ui)]. For nota-
tional simplicity, we denote Eη[Γ(ηi, Ui)] by Ωi(η).
Stacking the n linear models for ηˆi we get
ηˆ1
...
ηˆn
 = 1n ⊗ η + ζ, (4.12)
where ζ is the vector containing ζ1, . . . , ζn. Further,
E[ζ] = 1n ⊗ 0.
Cov[ζ] =

W + Ω1(η) 0 · · · 0
0 W + Ω2(η) · · · 0
...
...
. . .
...
0 0 · · · W + Ωn(η)

= I⊗W +

Ω1(η) 0 · · · 0
0 Ω2(η) · · · 0
...
...
. . .
...
0 0 · · · Ωn(η)

= V1 + V2.
The MINQUE theory for estimation of variance components provides an estimator for
W and η, which are the population level parameters. We use the iterative estimation
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methodology described in Chapter 3 to obtain the population estimators, Wˆ and ηˆ.
Estimator of the covariance of ηˆ is Wˆ + 1
n
∑n
i=1 Ωˆi, denoted by V̂. The methodology
is illustrated in Chapter 5 using simulated data examples and a real data example
from the benzene inhalation experiment.
4.2.2 Asymptotic Theory for the Proposed Estimators
First, we consider the asymptotic theory for individual parameter estimation. It can
be formulated in a similar vein as in Chapter 3 as a constrained non-linear parameter
estimation problem. The consistency of the estimated individual parameter values
(ηˆi) and the associated covariance matrix is Γ(ηi, Ui) is shown under the Assumptions
B.
Assumptions B:
(B.1) The components of the model function F(.) are continuous and twice
differentiable for η0 ∈ B, a closed ball, where η0 is the true parameter
vector.
(B.2) The matrix of partial derivatives D(η) =
dF
dη
is of full rank with
probability 1 in a neighborhood of η0.
(B.3) The matrix Bt = H
−1/2
t Λ(t)
′Λ(t)H−1/2t and B
−1
t converges to positive
definite matrices for large t, where Ht = diag(hiit) is a sequence
of diagonal matrices such that hiit →∞ as t→∞.
Lemma 4.1 Under Assumptions B, H
1/2
t (ηˆi − ηi) = Op(1) as t→∞.
Using Lemma 2.1 and delta method, the individual covariance matrix Γ(ηˆi, Ui) con-
verges to Γ(ηi, Ui) in probability.
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Lemma 4.2 Ωˆi
pr−→ Ωi as t→∞ for all i.
Proof To prove this lemma we need the following compactness condition on the
individual covariance matrices.
E
[
sup||<δ‖Γ′(ηi + , Ui)− Γ′(ηi, Ui)‖
]
→ 0, as δ → 0,
where Γ′(.) represents the derivative of Γ(.) with respect to ηi. The above condition
requires that
∥∥∥∂2Γ(ηi,Ui)∂η2i ∥∥∥ is bounded. Under these conditions,
Ωˆi = E(Γ(ηˆi, Ui))
= E[Γ(ηˆi − ηi + ηi, Ui)]
= E[Γ(ηi, Ui)] + E[E((ηˆi − ηi)Γ′(ηi, Ui))|ηi]
→ E[Γ(ηi, Ui)] as t→∞ (Using Lemma 2.1)
= Ωi
We now explore the large sample theory for the estimator of the population pa-
rameter η under the model specified by (4.12). We rewrite the model as
y∗ = M∗η + ζ∗, (4.13)
where
y∗ = (V1 + V2)−1/2(ηˆ1, . . . , ηˆn)
′,
M∗ = (V1 + V2)−1/2[I : · · · : I]′ =
n∑
i=1
(W + Ωi)
−1/2
and
ζ∗ = (V1 + V2)−1/2ζ.
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We assume here that η is independent of ζ∗ for developing the theory. Under Model
4.13, the generalized least square estimate of η is given by
η˜ = (M∗′M∗)−1M∗′y∗
= η + (M∗′M∗)−1M∗′ζ∗
= η + (
n∑
i=1
(W + Ωi)
−1)−1
n∑
i=1
(W + Ωi)
−1ζi
Let m∗i be the ith column of M
∗. If the variance components are known in this
framework, under the following conditions,
max1≤i≤n
[
m∗i
′(
n∑
i=1
(W + Ωi)
−1)m∗i
]→ 0 as n→∞, and
lim
n→∞
n−1(
n∑
i=1
(W + Ωi)
−1) = G(finite and positive definite),
the estimate of η, denoted by η˜ is asymptotically normal and
√
nt(η˜ − η) D−→ N (0,G−1)
However in the covariate setup explained earlier, the variance components V1 and V2
are unknown functions of η and the covariates Ui, and is estimated by V̂. Consider
the estimator ηˆ with the plug-in estimator of the covariance.
ηˆ = η +
( n∑
i=1
(Ŵ + Ωˆi)
−1
)−1 n∑
i=1
(Ŵ + Ωˆi)
−1ζi
Theorem 4.1 : Under the model in (4.7), let ηˆ be the proposed estimator. Under
the above Assumption B,
√
nt(ηˆ − η˜) pr−→ 0 as nt→∞.
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Proof :
ηˆ − η˜ =
[ n∑
i=1
(Ŵ + Ω̂i)
−1)−1 −
n∑
i=1
(W + Ωi)
−1)−1
]
[I′ : · · · : I′]V̂−1V1/2ζ∗
+
( n∑
i=1
(W + Ωi)
−1
)−1
[I′ : · · · : I′][V̂−1 −V−1]V1/2ζ∗.
We need two conditions for the result to hold :
(i) Largest eigenvalue of VV̂−1 are Op(1).
(ii) Largest eigenvalue of
(∑n
i=1 (W + Ωi)
−1
)(∑n
i=1 (Ŵ + Ωˆi)
−1
)−1
are op(1).
To evaluate these conditions we need to prove the following:
max
1≤i≤n
‖Ω−1i Ωˆi − I‖ → 0 as t, n→∞.
Consider any two non-null vectors x and y.Then,
x′
[
Ω−1i Ωˆi − I
]
y
'x′
[
Ω−1i {Ωi + E[(ηˆi − ηi)Γ′(ηi)]} − I
]
y
=x′E
[
E{(ηˆi − ηi)Γ′(ηi)|ηi}
]
y
=x′E
[
E{(ηˆi − ηi)|ηi}Γ′(ηi)
]
y
→0. [Using Lemma 2.1]
This implies (W + Ωi)
−1(Ŵ + Ωˆi)− Ip pr−→ 0. Hence both conditions (i) and (ii) hold
and the theorem holds.
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4.2.3 Testing Covariate Effects
Consider a study on multiple individuals that measures concentration of a chemical in
blood. We are interested in fitting a physiologically based pharmacokinetic (PBPK)
model to these data. The individuals in the study may have different values of the
covariates such as age, weight, gender or dose. Our objective is to test whether the
model parameter (and consequently the PBPK model) varies with the values of the
covariates. For example, if θm and θf represent the model parameters for male and
female subjects, a question of interest would be to test whether they are equal. In
case of a continuous covariate such as dose, one might be interested to test whether
the parameters change with dose.
Suppose we are interested in testing whether the parameters are dependent on the
1× q covariate vector Ui. Let θi = (θi1, . . . , θim) be a m× 1 model parameter vector
for the ith individual. The hypothesized model with a linear link function is
θik = η
0
ik + Uiη
∗
ik, k = 1, . . . ,m and i = 1, . . . , n.
Hence,
θi = η
0
i + diag(U1, . . . , Ui)η
∗
i
= η0i + Uiη
∗
i ,
where η∗i is of order mq × 1.
We assume that the true parameters ηi are independent and identically distributed
with mean η = (η0,η∗)′ and covariance matrix W. Accordingly, a general test of
hypothesis that no covariate effect is present can be written as H0 : Lη = 0 against
Ha : Lη 6= 0, where L is an appropriately chosen matrix. Consider the marginal
distribution of ηˆi, which has mean η and covariance W +Ωi. The test statistic based
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on the ηˆis would test whether these estimated parameter values are coming from a
distribution with a mean that has η∗ as 0.
The test statistic for such a test is given by
F =
(Lηˆ − Lη)′(Ĉov(ηˆ))−1(Lηˆ − Lη)
mq
,
where Ĉov(ηˆ) = Wˆ + 1
n
∑n
i=1 Ωˆi. Under H0,
F =
ηˆ′L′(Ĉov(ηˆ))−1Lηˆ
mq
H0∼ Fmq,n−mq.
We shall reject H0 at 100α% level of significance if the observed value of the test
statistic is greater than Fmq,n−mq(α).
4.3 Discussion
We have presented a methodology to evaluate effects of covariates on models governed
by differential equations. We extend the functional data analytic estimation method-
ology presented in Chapter 3 to a covariate testing framework. Both estimation and
testing of hypotheses for the parameters are developed in the presence of covariates.
We overcome the usual difficulties in testing for covariate effects in such complicated
models where the explicit form of dependence of response on the covariates is not
available. Since the solution of the system of differential equations is not required in
the proposed methodology, the covariates do not need to be included in the model. A
linear dependence of the model parameters on the covariates is used in this work. Due
to this approach, tests of hypotheses about covariate effects can be performed more
directly than in the approaches for non-linear regression. However, a non-parametric
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methodology for testing covariate effects may be explored if no specific form of the
functional dependence is assumed.
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Chapter 5
DATA EXAMPLES :
SIMULATED AND REAL DATA
In this section we present all the data examples, both simulated and real, to illustrate
the methodologies described in the previous chapters. The estimation methodology
described in Chapter 3 is illustrated using simulated data from the benzene PBPK
model and the benzene inhalation data. The methodology presented in Chapter 4
is illustrated using simulated data from a two compartment pharmacokinetic model
and is also tested on the benzene inhalation data example.
5.1 Simulated Example : Based on Benzene PBPK Model
In this section, we present simulated data based on the PBPK model of benzene
described earlier. The simulated example is designed according to the real data
example used in this paper. We simulated a random sample of four subjects such
that each subject is exposed to 161µg/m3 benzene through inhalation for two hours,
following which the subjects were provided with clean breathing air. Concentration
of benzene in exhaled breath at 5, 15, 30, 60, 90, 120 and 150 minutes post-exposure
is the response variable for each individual. The PBPK model is described in Section
2.1 and Equations (2.2)-(2.8) represent the differential equation model of interest.
We obtain population parameter estimates of the metabolic parameters along with
estimates of their variability.
We treat the maximum metabolic rates in liver and bone marrow as unknown
parameters. So θ = (Vmax(liv), Vmax(bm), km(liv), km(bm))
′ and it’s true population value
is taken as θ0 = (387, 80, 1.2, 17)′. We assume that the individual parameter values
θi
iid∼ N4
(
θ0, diag(50, 3, .01, .1) + J
)
, where J is a matrix of 1’s.
Concentration in venous blood (Xi) is obtained by solving the benzene PBPK
model equations given by Equations (2.2)-(2.8) using θi as the parameter. Finally
the data Yi is generated from N7(Xi,R). Here R is an intra-individual covariance
structure. We choose the (t, t′)th element of R as rt,t′ = 5 ∗ (0.2)|t−t′|. We look at 200
datasets consisting of four individuals each.
Linear combinations of nine B-splines of order four are used to approximate the
concentration of benzene in each compartment and the metabolites concentration.
Simulated annealing is applied to obtain the basis and model parameter estimates for
each individual. We use the iterative methodology described in Section 3.2.2 to obtain
the population parameter estimates and the corresponding variability estimates.
5.1.1 Results of Simulation Study
Table 5.1: Population parameter estimation results
Vmax(liv) Vmax(bm) km(liv) km(bm)
Units µg/min µg/min µg/l µg/l
True value 387.5 80 1.2 17
Estimate 386.4 80.05 1.33 12.99
Rel. MSE 1.13 0.67 0.87 0.76
Rel. Bias -0.58 0.05 0.11 -0.27
Results of the simulation study, summarized in Table 5.1, suggest that the pro-
posed methodology has a small relative bias and relative MSE (relative to true value
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of the parameter) for a sample size as small as 5.
The estimated coverage probability for a 90% joint confidence region of θ centered
at θˆ is 0.915 (s.e.= 0.0197). This suggests that even with a sample size as small as
five the proposed methodology yields reasonably accurate confidence regions for the
population parameter.
5.2 Real Data : Benzene Inhalation Experiment
Benzene is an ubiquitous chemical reported to be carcinogenic to humans and animals.
It is an important study chemical due to its extensive industrial usage and production
leading to widespread occupational exposure. Certain sources of non-occupational
exposure have also been identified, such as automobile exhaust and cigarette smoke.
Epidemiological evidence suggests an increased incidence of leukemia due to benzene
and its metabolites. It is of interest to us to investigate the mode of action of ben-
zene in human physiology. Several pharmacokinetic models have been proposed to
model the flow of benzene (Travis et al. (1990), Woodruff and Bois (1993)). These
are compartmental models with main tissues and metabolizing sites serving as the
compartments and blood acting as the mode of delivery within these tissues. The five
tissue groups are (1) Richly perfused tissues, (2) Slowly perfused tissues, (3) Fat, (4)
Liver and (5) Bone marrow. In case of a benzene pharmacokinetic model, it is com-
mon practice to include bone marrow as a separate tissue compartment since it is a
potential metabolizing site for a carcinogen like benzene. A schematic representation
of one such model is shown in Figure 1.1.
The differential equations describing the benzene PBPK model are given by (2.2)-
(2.8). We are using data from a benzene inhalation experiment on four individuals
where each individual was exposed to certain concentration of benzene through in-
haled air for two hours. At the end of two hours, benzene exposure was stopped and
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subjects were provided clean breathing air. Benzene concentrations (in µg/m3) were
measured in exhaled breath at 5, 15, 30, 60, 90, 120 and 150 minutes post exposure.
We use the benzene PBPK model mentioned earlier. The data are shown in Figure
5.1.
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Figure 5.1: Exhaled breath data for benzene inhalation experiment. Concentration
of benzene in exhaled breath (in µg/m3) was measured post-exposure. The black
dotted line represents the exposure stoppage time of 120 minutes.
Our objective of interest is to estimate and infer about the parameters describing
the physiologically based pharmacokinetic model using the exhaled breath concentra-
tion data.
5.2.1 Method and Results
For individual parameter estimation, nine B-splines of order four are used for approx-
imating each of the six compartments in the model. The observed time points are
used as the knots for fitting splines. The regularization parameter, λ, is taken to be
unknown and estimated for each individual within the individual estimation method-
ology. Using the estimated θˆi, we obtain the following fits from the solution of the
system of differential equations. In Table 5.2, we present the estimated parameter
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Figure 5.2: Individual parameter fits showing the estimated exhaled breath concen-
tration (in µg/m3) of benzene (solid black lines) for the four individuals obtained by
solving the differential equations with the estimated individual parameter values.
values for each individual in the study.
Table 5.2: Estimated values of the metabolic parameters for each individual in the
study.
Vmax(liv) Vmax(bm) km(liv) km(bm)
Individual 1 503.45 99.19 1.28 3.59
Individual 2 146.82 20.3 0.88 62.67
Individual 3 399.95 99.13 0.26 0.49
Individual 4 499.45 98.37 2.45 1.45
The estimated values of the intra-individual correlation coefficients ρi for the four
subjects are 0.146, 0.2434, 0.623 and 0.025. Estimated values of λ for the four individ-
uals are 2.38×10−5, 1.98×10−4, 1.06×10−4 and 1.37×10−6. The population parameter
estimates obtained are as follows:
Vˆmax(liv) = 387.41 µg/min, Vˆmax(bm) = 79.25 µg/min, kˆm(liv) = 1.22 µg/l, kˆm(bm) =
17.04 µg/l.
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V̂θ =

20556.87 4957.96 −307.30 471.16
4957.96 1292.01 −78.07 77.02
−307.30 −78.07 4.77 −7.08
471.16 77.02 −7.08 190.22

.
Consider an individual of weight 130 lbs given an exposure concentration of 161
µg/m3 for two hours. The post exposure population curve for such an individual with
the prediction intervals at observed time points are shown in Figure 5.3.
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Figure 5.3: Population fitted exhaled breath concentration of benzene with 95% pre-
diction intervals. The solid curve is obtained from the solution of the system of
differential equations in (2.2)-(2.8) using the value of the population parameter esti-
mate. The vertical lines represent the prediction intervals.
We analyze the predicted behavior of benzene as explained by the predicted sys-
tem of differential equations, obtained through the described methodology, in Figure
5.4. We consider the post exposure concentration of benzene in the different com-
partments of the PBPK model and exhaled breath across time with the solution of
the PBPK model using the estimated population parameters.
We investigate a few important features of the predicted model. For all the com-
partments and exhaled breath, the concentration reaches a peak at 120 minutes and
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Figure 5.4: Predicted compartmental concentrations (in µg/m3) over time. These
plots are obtained by solving the differential equation model given by (2.2)-(2.8) with
the estimated population model parameter estimates.
decreases post exposure. These plots give us an idea as to how and where the benzene
is being processed. Both fat and slowly perfused compartments show a slow decrease
in concentration than others, indicating an affinity of benzene towards these class
of tissues. As for the metabolizing sites, liver and bone marrow, the concentrations
decrease rapidly. This could indicate formation of metabolites of benzene in these
two sites. Also the rate of metabolization appears to be faster in liver than in bone
marrow. The ratio of the estimates of Vmax to those of km for the two metaboliz-
ing sites is 317.5 for liver and 4.66 for bone marrow. This might indicate different
enzymatic processes and activity in the two sites. The information here provides an
insight into the kinetic behavior of benzene which was one of our main objectives.
Further data on enzymatic reactions or metabolite concentrations could enhance the
quality of the inference in the given setup.
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5.3 Simulated Data : Covariate Effects in a Compartmental
Model
We present here a simulated data example based on a compartmental pharmacoki-
netic model to study the effect of covariates and illustrate the estimation methodology
presented in Chapter 4.
5.3.1 Pharmacokinetic Model Description
The model used for illustration is a two compartment pharmacokinetic model repre-
sented by Figure 5.5. The chemical is being absorbed through Compartment 1. Only
Compartment 1 
Compartment 2 
Vmax, km 
ka k10 
cin 
Figure 5.5: A two compartment pharmacokinetic model with linear and non-linear
kinetics.
a fraction of the given chemical concentration gets absorbed in Compartment 1 at a
rate of ka. The chemical gets removed from Compartment 1 at a rate k10. Further,
there is a formation of metabolites according to a non-linear Michaelis-Menten kinet-
ics in Compartment 2.
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The system of differential equations describing the compartmental model shown
in Figure 5.5 is given by (5.1). The rates of change in concentration of chemical in
the two compartments (c1, c2) and the excreted concentration (c3) are given by
Compartment 1 :
dc1
dt
= kacin − k10c1 − Vmaxc1
km + c1
,
Compartment 2 :
dc2
dt
=
Vmaxc1
km + c1
,
Excreted chemical :
dc3
dt
= k10c1,

ODE Model (5.1)
where cin represents the exposure concentration which is non-zero up to four hours of
exposure and zero after that. The parameters k10 and ka are assumed to be known
and fixed at 0.2 and 0.9 respectively. The metabolic parameters Vmax and km com-
prise the unknown parameters (θ).
5.3.2 Study Design for Simulations
For simulating a dataset based on covariates, we design a study for n(= 5) individuals.
Each of these n individuals are subjected to one of the four exposure concentrations
(3, 5, 7, 10 mg/L) of interest. A continuous exposure is provided for four hours and
after that the exposure is stopped. The concentration in Compartment 1 is observed
both during and after exposure for each subject at 1, 1.5, 2, 3, 4, 5 and 7 hours
from the beginning of the study. The concentration in Compartment 1 is the only
observable quantity. To build a covariate effect of exposure concentration, we assume
that the unknown parameters are functions of the exposure concentration (excon) for
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each individual,
log(Vmax(i)) = η0v + η1v ∗ exconi
log(km(i)) = η0k + η1k ∗ exconi.
 Covariate effects. (5.2)
The true population parameter values for η = (η0v, η1v, η0k, η1k)
′ is (0.50, 0.20, 1.00, 0.20)′.
Figure 5.6 shows the behavior of the observable state variable under the above covari-
ate model for different exposure concentrations. The new individual parameters (ηi)
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Figure 5.6: The simulated behavior of the observable state variable (Compartment 1)
for different exposure concentrations under a log-linear covariate model for the two
compartment pharmacokinetic model. Exposure concentrations (excon) are in units
of mg/L.
are generated from a four variate normal distribution with mean (0.50, 0.20, 1, 0.20)′
and covariance matrix W where
W =

0.01 0.001 0.005 0
0.001 0.01 0 0.005
0.005 0 0.05 0.001
0 0.005 0.001 0.01

.
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The generated parameter values (ηi) are used in (5.2) to solve the system of ODEs
(5.1) to obtain a location parameter for the response distribution. To introduce
intra-individual variability, a random multivariate normal error term with mean 0
and covariance matrix Σ of order seven is added to the mean response for each
individual. The (k, k′)th element of Σ is
Σkk′ =

√
sk k = k
′,√
(sksk′)0.1
|tk−tk′ | k 6= k′,
where k, k′ = 1, . . . , 7 and s = (s1, . . . , s7)′ = (.05, .3, .3, .3, .4, .001, .00001)′. The
simulations were repeated for 100 datasets, with five individuals in each, based on
the same study design.
5.3.3 Results of the Simulated Example
Individual and population parameter estimation is carried out according to the method-
ology described in Chapter 4. Linear combinations of nine B-spline functions of order
four are used to approximate the state variables. The results of the population esti-
mation are summarized in Table 5.3. The estimated coverage probability for a 90%
Table 5.3: Population parameter estimation results in simulation of covariate effects.
η0v η1v η0k η1k
True value 0.50 0.20 1.00 0.20
Estimate 0.507 0.213 0.984 0.21
Rel. MSE (%) 1.5 1.72 3.16 1.40
Rel. Bias (%) 1.46 6.43 -1.56 4.82
joint confidence region of η centered at ηˆ is 0.925 (s.e.= 0.0263). This suggests that
even with a sample size as small as five the proposed methodology yields reasonably
accurate confidence regions for the population parameter.
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5.4 Benzene Inhalation Experiment : Covariate Analysis
We consider the experiment conducted by Yu (1995) on Benzene inhalation to study
the effect of covariates on kinetics of benzene. We consider the PBPK model given
by (2.2)-(2.8) as the system for modeling the kinetic process. Recall that the PBPK
model does not specifically mention any covariates that may affect the parameters
involved. For the purpose of illustration, we take exposure concentration as a contin-
uous covariate in this experiment.
In this experiment, four individuals were given four different exposure concen-
trations of benzene through inhaled air for two hours, following which the exposure
was stopped and concentration of benzene was measured in exhaled breath at specific
time points. Benzene concentrations (in µg/m3) were measured in exhaled breath at
5, 15, 30, 60, 90, 120 and 150 minutes post exposure. We are interested in inferring
about the parameters in the PBPK model while adjusting for covariates. We consider
the metabolic parameters Vmax(liv) and Vmax(bm) as the unknown parameters in the
PBPK model. All other parameters are assumed to be known.
We assume the following model to incorporate covariates in the PBPK model.
Vmax(liv) = η01 + η11 ∗ excon,
Vmax(bm) = η02 + η12 ∗ excon,
 (5.3)
where excon represents exposure concentration. Hence the new parameter to be
estimated is η = (η01, η11, η02, η12)
′ for each of the four individuals. The individual
estimation results are shown in Table 5.4.
We use the individual parameter estimates to perform a population estimation for
η. Using the iterative algorithm mentioned in Chapter 4 and Chapter 5, we obtain
the population parameter estimates as ηˆ0v = 387.57, ηˆ1v = 0.0093, ηˆ0k = 80.02 and
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Table 5.4: Individual parameter estimation results for benzene data with dose as a
continuous covariate.
η0v η1v η0k η1k
Individual 1 499.85 0.0059 99.85 0.0049
Individual 2 150.45 0.0048 20.22 0.0070
Individual 3 399.99 0.0048 100.00 0.0051
Individual 4 499.98 0.0216 100.02 0.0043
ηˆ1k = 0.0053.
The estimated population variability is given by the matrix

20405.80 0.504 4725.55 −0.14
0.504 7.565275× 10−5 0.090 −1.35× 10−5
4725.55 0.090 1192.03 −0.033
−0.14 −1.35× 10−5 −0.033 2.87× 10−5

.
The population predicted curve for a typical subject with weight of 130 lbs given
an exposure concentration of 161.5 µg/m3 under the same study scheme is shown in
Figure 5.7 with 95% prediction intervals at the observed time points.
In order to test whether the covariate effects estimated in this real example are
significant, we use the Wald type test developed in Chapter 4. The test of hypothesis
can be written as
H0 :
η1v
η1k
 =
0
0
 .
We can rewrite the null hypothesis as H0 : Lη = 0, where L =
0 1 0 0
0 0 0 1
.
The test statistic is F = (Lηˆ−Lη)
′(Ĉov(ηˆ))−1(Lηˆ−Lη)
2
. The observed value of F under
H0 is 1.495. Comparing with the null distribution which is F2,4−2, observed F is
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Figure 5.7: Population predicted exhaled breath concentration of benzene along with
95% prediction intervals for a typical person given an exposure concentration of
161.5µg/m3 of benzene. The vertical black solid lines represent the 95% prediction
intervals.
statistically insignificant at 95% level of significance. Hence in light of the given
sample and linear covariate model, we may conclude that exposure concentration
does not affect the metabolic parameters significantly. However, in cases where more
data are available, we may consider more detailed models with more parameters to
map the relation between the model parameters and covariates.
5.5 Discussion
In this chapter, numerical results from the simulated examples and the real data ap-
plications have been presented. First, we summarize the findings from the numerical
examples to illustrate the methodology developed in Chapter 3. From the results of
both the simulated data example based on the benzene PBPK model and the real
benzene inhalation data, we observe that the individual parameter estimation pro-
vides close basis approximations to the observed data points. We obtained estimates
of both intra and inter-individual variability along with the individual and population
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parameter estimates. We also construct valid prediction intervals for the population
curve at the observed time points thus providing a complete statistical framework for
this problem. The methodology does away with the need to solve the system of dif-
ferential equation in order to obtain parameter estimates. This reduces computation
time considerably and also takes into account the fact that the differential equations
may not capture underlying biological phenomenon accurately. Using the popula-
tion parameter estimates, we have shown the prediction for the chemical kinetics of
benzene in observable as well as unobservable compartments using the population
parameter estimates. The methodology has been shown to work well for sample sizes
as small as four and this is an advantage in many toxicological studies, where number
of subjects are small.
The proposed methodology also provides a foundation for inclusion and estimation
of covariate effects and thus provides a feasible alternative to existing methodologies
for models governed by system of differential equations. This has been illustrated
through the simulated data examples and the real benzene inhalation data. We pre-
sented simulated examples based on a compartmental model using covariates. In case
of a single covariate, the results provide small relative mean squared errors and biases
for the true population values. Hence we can capture the covariate effects well in
case they are truly affecting the parameter values and hence the differential equation
model. The methodology when applied to the benzene inhalation data with a linear
model of dependence, does not reveal any significant effect of exposure concentration
on the maximum metabolic rates for bone marrow and liver.
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Chapter 6
FUTURE RESEARCH
DIRECTIONS
Keeping with the present and planned work on developing methodology for modeling
systems of differential equations, we present in this chapter some directions for fu-
ture research some of which can serve as ideas for postdoctoral work. The objective
of this dissertation was to develop a formal methodology for analyzing systems gov-
erned by differential equations which can be applied to a variety of areas. The current
work tries to estimate and infer about the population model parameters taking into
account the intra and inter-individual variability that may exist in the data. The
underlying system/phenomenon was represented using a multi-compartment system
of ordinary differential equations (ODE). Individuals were observed for measurements
on one or more of the compartments over time. The methodology consisted of individ-
ual parameter estimation and population parameter estimation using the estimated
individual parameter values under a hierarchical model structure. The inclusion and
testing of covariates in models defined by differential equations is also accomplished
in this work. A functional data analytic methodology has been developed in this
work motivated by physiologically based pharmacokinetic modeling which enhances
the literature on analysis of such models. The statistical framework allows for infer-
ence avoiding the solution for differential equations which is novel in case of PK and
PBPK modeling situations. Toxicologists can use the methodology to infer about
individuals separately as well as the population while making minimal assumptions
about the distributions of the data even for small sample sizes, while obtaining valid
variance component estimates. Apart from toxicology and pharmacology, the pro-
posed methodology has potential for use in several other fields that involve modeling
using differential equations to infer about individual and population patterns.
The methods developed here are for a general class of models defined by a sys-
tem of ordinary differential equations. Often in modeling of biological, chemical or
environmental phenomena, other classes of differential equations such as partial dif-
ferential equations (PDE), stochastic differential equations (SDE) or time delayed
differential equations are used for mathematical modeling. Each of these classes of
equation have different structures and hence the statistical methodology for analyzing
these systems needs attention. The functional data analytic methodology is yet to be
extended to apply to such situations and hence serves as an important methodological
area of research.
Often complex networks comprise of several interconnected modules where each
module can be modeled using systems of differential equations. For instance, in
studying the pharmacokinetics of a pregnant mother, one has to take into account
the chemical kinetics in the fetus. Also in metabolic pathways, different chemical
processes take place simultaneously or in a synchronized manner. For example, in
different metabolizing sites of the human body, several enzymes metabolize various
chemicals. In order to achieve a better understanding of chemical kinetics and mech-
anism of action, these information need to be incorporated along with pharmacoki-
netics. Developing a statistical methodology for such problems require the synthesis
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of results from the differential equations systems defining different modules in the
system.
Physiologically based pharmacokinetic modeling in itself presents ample opportu-
nities for methodological research. Design of studies for PBPK model analysis is one
of the valid questions. There are several unobserved compartments with one or two
observable response variables in a typical pharmacokinetic study. This often poses
a problem in analyzing high dimensional ODEs especially in genetic models. More
research is needed to develop better designs for analysis using such models.
Exposure to harmful chemicals is often occupational and long-term in nature for
human subjects. In some other cases, there may also be exposure to mixture of chem-
icals over a certain period of time. For instance, exposure to pollutants in air involves
exposure to different kinds of chemical. Also there may exist multiple routes of expo-
sure like dermal, ingestion and inhalation. These situations call for more realistic and
complex models that account for such varied conditions. The proposed methodology
need to be modified for analyzing such models and infer about the relative harms
being caused by these exposures.
Analysis of gene regulatory networks (GRN) is a flourishing area of research. Or-
dinary differential equations serve as a major technique in modeling regulatory net-
works. A recent paper (Polynikis et al. 2009) compares different modeling approaches
for modeling GRN. Simplified ODE models based on quasi-steady-state assumption of
mRNA concentrations and non-linear Hill functions are used to describe the processes
of translation, transcription and degradation. A sample ODE system from (Polynikis
et al. 2009) is shown below. For each gene i, two ODEs are used to describe the
rate of change in transcribed mRNA concentration (ri) and the rate of change in the
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translated protein (pi).
Transcription :
dri
dt
= F (fRi (p1), . . . , f
R
i (pn))− γiri,
Translation :
dpi
dt
= fPi (ri)− δipi,
where i = 1, . . . , n. The functions fRi (pi) describe the dependence of mRNA concen-
tration on protein concentration and are usually non-linear. Translation is described
by the function fPi (ri). The other terms represent the degradation of mRNA and
protein. The structure of the problem lends itself perfectly to the functional data an-
alytic methodology for estimation of the parameters in this model. However, the high
dimensionality of the problem needs to be balanced with the data available since gene
expression profiles may not be available for all genes. The methodology developed
in this dissertation may be used to identify or reconstruct the regulatory networks
involving the candidate genes, taking into account the covariates that may occur in
a genetic study.
Similarly, study of viral dynamics poses a problem that can be modeled using
systems of differential equations and hence is a potential area of application for the
proposed methodology. Consider a group of subjects being treated for influenza. We
might be interested in studying the dynamics of the infection by flu virus and its
effects on the human physiology from the start of treatment till remission or death.
A system of differential equations can be formulated to capture the rates of change
in the densities of na¨ıve cells, infected cells and viral load. The infection process
involves na¨ıve cells getting infected by the virus, and these infected cells may die or
recover over time. These processes may be affected by the rates of infection, rate
of death and/or the factors determining the proliferation of the virus. Individual
immune response and treatment received in form of medications also have an effect
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on infections. Developing and analyzing such ODE based models in such fields would
help in enhancing and validating the methodology developed in this dissertation.
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